CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 128,543	$ 169,526
Marketable securities	80,206	118,737
Research and development prepaid expenses	12,863	13,424
Other prepaid expenses and current assets	3,918	4,501
Total current assets	225,530	306,188
Restricted cash, non-current	1,162	1,106
Property and equipment, net	20,328	20,968
Operating lease right-of-use assets, net	14,233	12,723
Other long-term assets	45	7
Total assets	261,298	340,992
Current liabilities:
Accounts payable	7,473	9,624
Research and development accrued expenses	34,699	29,149
Other accrued expenses and current liabilities	15,733	10,580
Operating lease liabilities, current	2,545	1,557
Total current liabilities	60,450	50,910
Deferred revenue, non-current	2,611
Operating lease liabilities, non-current	29,335	29,165
Share repurchase liability	588	813
Total liabilities	92,984	80,888
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2025 and December 31, 2024
Additional paid-in capital	925,831	918,610
Accumulated other comprehensive income (loss)	(8)	40
Accumulated deficit	(757,514)	(658,551)
Total stockholders' equity	168,314	260,104
Total liabilities, redeemable convertible preferred stock and stockholders' equity	261,298	340,992
Voting common stock
Stockholders' equity:
Common Stock	4	4
Non-voting common stock
Stockholders' equity:
Common Stock	$ 1	$ 1